Product Spotlight: Glycogen Synthase Kinase Inhibitors
 |
| |
| Glycogen Synthase Kinase-3b (GSK-3b), a highly conserved, ubiquitously expressed serine/threonine protein kinase, is involved in the signal transduction cascades of multiple cellular processes. It is negatively regulated by protein kinase B/Akt and by the Wnt signaling pathway. Higher levels of GSK-3b have been shown in pre-tangle and in phosphorylated tau-bearing neurons. Overexpression of GSK-3b is a characteristic feature of Alzheimer's disease. GSK-3b accounts for most major phosphorylation sites of fetal and paired helical filament-tau. b-Amyloid peptides are shown to activate GSK-3b, suggesting that activation of GSK-3b is a key mechanism in pathogenesis of Alzheimer's disease. The development of GSK-3 inhibitors holds considerable promise for reducing tau phosphorylation and debilitating effects of Alzheimer's disease. |
| |
| |
1-Azakenpaullone (Cat. No. 191500)
A Kenpaullone (Cat. No. 422000) analog that acts as a potent and ATP-competitive inhibitor of GSK-3b (IC50 = 18 nM), and displays ~ 100 - 200 fold greater selectivity over Cdk1/B and Cdk5/p35 (IC50 = 2.0 mM and 4.2 mM, respectively). |
| |
Aloisine A (Cat. No. 128125)
An inhibitor of GSK-3 (IC50 = 500 nM for GSK-3a and 1.5 mM for GSK-3b). Also acts as a potent, selective, reversible, and ATP-competitive inhibitor of Cdks (IC50 = 150 nM for Cdk1/ cyclin B, 120 nM for Cdk2/cyclin A, 400 nM for Cdk2/cyclin E, and 160 nM for Cdk5/p35). |
| |
Aloisine, RP106 (Cat. No. 128135)
A cell-permeable, potent, selective ATP-competitive inhibitor of Cdk1/cyclin B (IC50 = 700 nM), Cdk5/p25 (IC50 = 1.5 mM), and GSK-3 (IC50 = 920 nM). |
| |
Alsterpaullone (Cat. No. 126870)
A potent inhibitor of Cdk1/cyclin B (IC50 = 35 nM). Displays remarkable in vitro antitumor activity. Inhibits Tau phosphorylation at sites that are typically phosphorylated by GSK-3b in Alzheimer’s disease. Also inhibits Cdk5/p25-dependent phosphorylation of DARPP-32. |
| |
FRATtide (Cat. No. 344265)
A peptide corresponding to amino acids 188 - 226 of FRAT1 (frequently rearranged in advanced T-cell lymphomas 1), a mammalian homolog of GSK-3 binding protein. Binds to the C-terminal lobe of GSK-3 and prevents the binding of “unprimed” substrates such as axin, b-catenin and tau. Exhibits little effect on GSK-3 catalyzed phosphorylation of “primed” (pre-phosphorylated) substrates such as glycogen synthase and eIF2B. |
| |
GSK-3 Inhibitor IX in Solution (Cat. No. 361552)
Supplied as a 10 mM (500 mg/140 ml) solution of GSK-3 Inhibitor IX (Cat. No. 361550) in DMSO. |
| |
GSK-3 Inhibitor X (Cat No. 361551)
An acetoxime analog of BIO, GSK-3 Inhibitor IX (Cat. No. 361550) that exhibits greater selectivity for GSK-3a/b (IC50 = 0.01 mM) over CDK5/p25, CDK2/A and CDK1/B (IC50 = 2.4 mM, 4.3 mM and 63 mM, respectively). |
| |
GSK-3 Inhibitor XIII (Cat. No. 361555)
An aminopyrazole compound that acts as a potent and ATP-binding site inhibitor of GSK-3 with a Ki of 24 nM. |
| |
GSK-3 Inhibitor XIV, Control, MeBIO (Cat. No. 361556)
A cell-permeable N-methylated analog of GSK-3 Inhibitor IX, BIO (Cat. No. 361550) that serves as a relevant kinase inactive control (IC50 > 92 mM for Cdk1/B, and > 100 mM for Cdk5/p25 and GSK-3a/b). |
| |
NEW! GSK-3 Inhibitor XV (Cat. No. 361558)
A cell-permeable pyridocarbazolo-cyclopentadienyl Ruthenium complex that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3 (IC50 = 0.7 nM and 1.1 nM for GSK-3a and GSK-3b, respectively) with moderate selectivity over PIM-1 kinase (IC50 = 6 nM). Its (R)-enantiomer (IC50 = 350 pM, 550 PM and 35 nM for GSK-3a, GSK-3b and PIM-1 kinase, respectively) is shown to increase the levels of b-Catenin and activate Wnt pathway in HEK293OT and 1205Lu melanoma cells at 25 nM, and induce a phenotype change in Zebrafish embryo at 1 mM.
|
| |
GSK-3b Inhibitor I (Cat. No. 361540)
A thiadiazolidinone (TDZD) analog that acts as a highly selective, non-ATP competitive inhibitor of GSK-3b (IC50 = 2 mM). Proposed to bind to the active site of GSK-3b. |
| |
GSK-3b Inhibitor II (Cat. No. 361541)
A 2-thio-[1,3,4]-oxadiazole-pyridyl derivative that acts as a potent inhibitor of GSK-3b (IC50 = 390 nM). |
| |
GSK-3b Inhibitor III (Cat. No. 361542)
An oxothiadiazolidine-3-thione analog that acts as a non-ATP competitive inhibitor of GSK-3b (IC50 = 10 mM). |
| |
GSK-3b Inhibitor VI (Cat. No. 361547)
A thienyl a-chloromethyl ketone compound that acts as a cell-permeable, irreversible, and non-ATP competitive inhibitor of GSK-3b (IC50 = 1 mM). This reactive alkylating agent is selective towards GSK-3b and does not affect PKA activity even at concentrations as high as 100 mM. |
| |
GSK-3b Inhibitor VII (Cat. No. 361548)
A cell-permeable, selective, irreversible, and non-ATP competitive inhibitor of GSK-3b (IC50 = 500 nM). |
| |
GSK-3b Inhibitor VIII (Cat. No. 361549)
A cell-permeable, potent, and highly specific inhibitor of glycogen synthase kinase-3b (GSK-3b) (IC50 = 104 nM). Inhibition is competitive with respect to ATP (Ki = 38 nM). |
| |
GSK-3b Inhibitor IX (Cat. No. 361550)
A cell-permeable, highly potent, selective, reversible, and ATP-competitive inhibitor of GSK-3a/b (IC50 = 5 nM). At higher concentrations, inhibits Cdk2/cyclin A (IC50 = 300 nM) and Cdk5/p25 (IC50 = 83 nM). |
| |
GSK-3b Inhibitor XI (Cat No. 361553)
A cell-permeable azaindolylmaleimide compound that acts as a potent, specific, and ATP-competitive inhibitor of GSK-3b (Ki = 25 nM) and minimally inhibits a panel of 79 commonly studied protein kinases, including several PKC isozymes. |
| |
GSK-3b Inhibitor XII, TWS119 (Cat. No. 361554)
A cell-permeable pyrrolopyrimidine compound that acts as a potent and selective inhibitor of GSK-3b (IC50 = 30 nM). |
| |
GSK-3b Peptide Inhibitor (Cat. No. 361545)
A phosphorylated peptide that acts as a substrate-specific, competitive inhibitor of GSK-3b (IC50 = 150 mM). Inhibits Cdc2, CK II, MAPK, PKA, PKB, and PKCd at higher concentrations (200 mM results in 85 - 100% inhibition). |
| |
GSK-3b Peptide Inhibitor, Cell-Permeable (Cat. No. 361546)
A cell-permeable, myristoylated form of GSK-3b Peptide Inhibitor (Cat. No. 361545) with a glycine spacer. Acts as a selective, substrate-specific, competitive inhibitor of GSK-3b (IC50 = 40 mM). Does not affect the activities of Cdc2, PKB, or PKC. |
| |
Indirubin-3'-monoxime (Cat. No. 402085)
A potent cell-permeable inhibitor of GSK-3b (IC50 = 190 nM) and cyclin-dependent kinases (IC50 = 180 nM for Cdk1). |
| |
Indirubin-3'-monoxime, 5-Iodo- (Cat. No. 402086)
A highly potent, cell-permeable inhibitor of GSK-3b (IC50 = 9 nM). Reported to inhibit GSK-3b phosphorylation of human tau protein in vitro (IC50 ~100 nM) and in cells (effective concentration = 20 mM). Also inhibits Cdk1 (IC50 = 25 nM) and Cdk5 (IC50 = 20 nM). |
| |
Indirubin-3'-monoxime-5-sulfonic Acid (Cat. No. 402088)
A highly potent, selective, ATP competitive inhibitor of Cdks 1 and 5 (IC50 = 5 nM for Cdk1; IC50 = 7 nM for Cdk5). Also acts as a potent inhibitor of GSK-3b (IC50 = 80 nM). |
| |
Kenpaullone (Cat. No. 422000)
A potent, cell-permeable, ATP competitive inhibitor of GSK-3b (IC50 = 230 nM), Lck (IC50 = 470 nM) and Cdks. Inhibits Cdk1/cyclin B (IC50 = 400 nM), CdK2/cyclin A (IC50 = 680 nM), Cdk2/cyclin E (IC50 = 7.5 mM), and Cdk5/p25 (IC50 = 850 nM). |
| |
| Other GSK-3 Products |
| GSK-3 Antibodies |
| GSK-3 Substrates |
| GSK-3 Enzymes |
|
